BETA: Please send your feedback!
BAE Systems
BA-GB:LON
Aerospace & Defense
$200.33bn
LARGE cap
$356.01
(1.60%)
0.10%
since start of 2019
40.97
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 2
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 1994
Exelixis, Inc. is a biopharmaceutical company. It engages in the developing and commercializing small molecule therapies for the treatment of cancer. The company brands include comertriq and cobimetinib. Its pipeline consists of cabozantinib, cobimetinib and Xl 888. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.
website
Headquarters
Executives
| Name | Title | Gender |
| Lynn C. Minella | Director-Group Human Resources | Female |
| Roger M. Carr | Chairman | Male |
| Philip Bramwell | Group General Counsel | Male |
| Charles Nicolas Woodburn, PhD, MBA | Chief Operating Officer & Executive Director | Male |
| Ian Graham King | Chief Executive Officer & Executive Director | Male |
| Peter J. Lynas | Executive Director & Group Finance Director | Male |
| Martin Cooper | Director-Investor Relations | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 2
Exelixis - Competitors and Related Companies
How Exelixis stacks up to its peers in the Biotechnology industry or with competing business segments.
Exelixis
EXEL:NAS
Biotechnology
$6.07bn
MID cap
$20.05
(-0.57%)
-0.02%
since start of 2019
9.37
Loading…